Insmed (INSM) Projected to Post Earnings on Thursday

Insmed (NASDAQ:INSM) will likely be releasing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Insmed to post earnings of ($1.35) per share and revenue of $114.3320 million for the quarter. Insmed has set its FY 2025 guidance at EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:00 AM ET.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. The business’s revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.94) earnings per share. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Insmed Stock Down 3.0%

INSM opened at $160.40 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. Insmed has a 1 year low of $60.40 and a 1 year high of $168.21. The firm has a 50 day moving average price of $146.10 and a 200 day moving average price of $106.75. The company has a market cap of $33.91 billion, a PE ratio of -28.09 and a beta of 1.03.

Analyst Ratings Changes

A number of analysts recently weighed in on INSM shares. Truist Financial upped their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. Morgan Stanley upped their target price on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Evercore ISI reiterated an “outperform” rating and issued a $180.00 target price on shares of Insmed in a research note on Wednesday, October 1st. William Blair assumed coverage on Insmed in a research report on Wednesday, August 20th. They set an “outperform” rating on the stock. Finally, UBS Group lifted their price target on shares of Insmed from $140.00 to $194.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $152.88.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 6,865 shares of the firm’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $128.40, for a total value of $881,466.00. Following the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at approximately $30,035,841.60. This trade represents a 2.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of Insmed stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the completion of the transaction, the insider directly owned 36,461 shares of the company’s stock, valued at $5,303,252.45. This trade represents a 67.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 152,657 shares of company stock worth $21,442,198. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Insmed

Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its holdings in shares of Insmed by 65.6% during the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 263 shares during the last quarter. Quantinno Capital Management LP boosted its position in Insmed by 24.5% during the 2nd quarter. Quantinno Capital Management LP now owns 4,468 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 878 shares during the period. Tidal Investments LLC boosted its position in Insmed by 41.8% during the 2nd quarter. Tidal Investments LLC now owns 4,035 shares of the biopharmaceutical company’s stock valued at $406,000 after purchasing an additional 1,189 shares during the period. Snowden Capital Advisors LLC grew its stake in Insmed by 23.8% during the 2nd quarter. Snowden Capital Advisors LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 1,483 shares during the last quarter. Finally, Sender Co & Partners Inc. acquired a new stake in Insmed in the second quarter worth $218,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.